- |||||||||| 4D-310 / 4D Molecular Therap
Enrollment open, Trial completion date, Trial primary completion date: 4D-310 in Adults With Fabry Disease and Cardiac Involvement (clinicaltrials.gov) - Feb 21, 2025
P1/2, N=18, Recruiting,
Active, not recruiting --> Recruiting | Trial completion date: Jan 2030 --> Jun 2030 | Trial primary completion date: Jan 2026 --> Jun 2026
- |||||||||| 4D-310 / 4D Molecular Therap
Trial completion date, Trial primary completion date: 4D-310 in Adults With Fabry Disease and Cardiac Involvement (clinicaltrials.gov) - Apr 8, 2024
P1/2, N=18, Active, not recruiting,
Active, not recruiting --> Recruiting | Trial completion date: Jan 2030 --> Jun 2030 | Trial primary completion date: Jan 2026 --> Jun 2026 Trial completion date: May 2028 --> Jan 2030 | Trial primary completion date: May 2024 --> Jan 2026
- |||||||||| 4D-310 / 4D Molecular Therap
Trial completion date, Trial primary completion date, Gene therapy: An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease (clinicaltrials.gov) - Apr 7, 2024
P1/2, N=18, Active, not recruiting,
Trial completion date: May 2028 --> Jan 2030 | Trial primary completion date: May 2024 --> Jan 2026 Trial completion date: Jun 2027 --> Jun 2030 | Trial primary completion date: Jun 2023 --> Jan 2026
- |||||||||| 4D-310 / 4D Molecular Therap
Enrollment closed: 4D-310 in Adults With Fabry Disease and Cardiac Involvement (clinicaltrials.gov) - Jan 31, 2023
P1/2, N=18, Active, not recruiting,
Trial completion date: Jun 2027 --> Jun 2030 | Trial primary completion date: Jun 2023 --> Jan 2026 Recruiting --> Active, not recruiting
- |||||||||| 4D-310 / 4D Molecular Therap
Enrollment closed, Trial primary completion date, Gene therapy: An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease (clinicaltrials.gov) - Jan 31, 2023
P1/2, N=18, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Jun 2023
- |||||||||| 4D-310 / 4D Molecular Therap
[VIRTUAL] Development of Novel AAV-Based Gene Therapy for Cardiac Disease () - Mar 14, 2021 - Abstract #ATS2021ATS_4734;
After completing all preclinical and IND-enabling studies in normal and Fabry mice, we performed a dose-ranging study in NHPs using C102 carrying GLA (4D-310)...The tropism of this novel AAV variant, C102, represents a significant advance over conventional AAVs and is well suited for the development of gene therapies for diseases where cardiac involvement is primary or syndromic, such as FD. Since the therapeutic transgene can readily be switched (modularity), the C102 capsid could be the gene therapy vehicle to treat any number of cardiovascular diseases.
- |||||||||| 4D-310 / 4D Molecular Therap
Enrollment open, Gene therapy: An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease (clinicaltrials.gov) - Sep 29, 2020
P1/2, N=18, Recruiting,
Since the therapeutic transgene can readily be switched (modularity), the C102 capsid could be the gene therapy vehicle to treat any number of cardiovascular diseases. Not yet recruiting --> Recruiting
|
